Dr. Welslau on the Rationale for Rituximab Biosimilar Combination in DLBCL | OncLive

Dr. Welslau on the Rationale for Rituximab Biosimilar Combination in DLBCL

June 29, 2020

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the rationale for investigating the Sandoz rituximab (Rituxan) biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma (DLBCL).

As part of the 2020 ASCO Virtual Scientific Program, findings from a real-world, prospective, post-approval study of the rituximab biosimilar plus CHOP provided additional evidence regarding the expected efficacy and safety profile of the combination in patients with previously untreated DLBCL.

The trial evaluated the agent in over 30 centers in Germany, says Welslau. Moreover, Rixathon continues to demonstrate clinical similarity to its biologic counterpart.


x